Market Place
Sourcing Support
Amgen Launches Trial for Switchers from Rival Obesity Drugs
01 May 2026 //
ENDPOINTS
China Signs Off On Amgen`s Imdelltra
10 Apr 2026 //
FIERCE PHARMA
Amgen Awards Bradway With $24.7M Pay Package In `25
08 Apr 2026 //
FIERCE PHARMA
Amgen scores with trial of on-body injected version of Tepezza
06 Apr 2026 //
PRESS RELEASE
Viridian`s Tepezza Rival Scores Ph. 3 Win, But Investors Unsure
31 Mar 2026 //
FIERCE BIOTECH
BMS` Celmod Drug Improves Myeloma PFS In Phase 3
09 Mar 2026 //
FIERCE BIOTECH
North Carolina Attracts Amgen, Roche For Next-Gen Obesity Drug
03 Mar 2026 //
BIOSPACE
Matterworks Announces Update to Leadership Team
17 Feb 2026 //
PR NEWSWIRE
OX40, Roche-Sanegene, Daiichi—Fierce Pharma Asia
06 Feb 2026 //
FIERCE PHARMA
Amgen Terminates Autoimmune Partnership With Kyowa Kirin
02 Feb 2026 //
BIOSPACE
DISCO Pharma Licenses Novel Cancer Surfaceome Targeted Therapies
07 Jan 2026 //
GLOBENEWSWIRE
Dark Blue Therapeutics Acquired By Amgen For Up To $840 Million
06 Jan 2026 //
PR NEWSWIRE
Abbvie Counters Amgen, Invests $100M In Trispecific Lung Cancer
05 Jan 2026 //
BIOSPACE
Inductive Bio Secures $21M To Enhance AI Drug Toxicity Models
08 Dec 2025 //
PR NEWSWIRE
Amgen signs on as 2026 World Cup host city supporter in LA
08 Dec 2025 //
FIERCE PHARMA
Biocon Biologics Settles With Amgen For Denosumab Biosimilars
02 Dec 2025 //
EXPRESSPHARMA
Avantor Wins 2025 Edison Patent Award For Viral Inactivation Tech
25 Nov 2025 //
PR NEWSWIRE
ImmunoScape Advances Next-Gen Cell Therapy, Adds Key Leaders
13 Nov 2025 //
BUSINESSWIRE
Amgen Halts Gastric Cancer Trial After Subpar Efficacy Analysis
05 Nov 2025 //
FIERCE BIOTECH
Amgen CEO Critiques FDA Push To Reform Biosimilars Market
05 Nov 2025 //
FIERCE PHARMA
Italian Biotech Raises $141M Series B To Fund Eye Gene Therapies
04 Nov 2025 //
FIERCE BIOTECH
Amgen to Present Repatha Phase 3 Data at AHA Scientific Sessions
31 Oct 2025 //
PR NEWSWIRE
Tezspire Approved for Chronic Rhinosinusitis with Nasal Polyps
20 Oct 2025 //
PRESS RELEASE
Amgen`s Phase III Data Supports FDA Label Expansion Of Repatha
05 Oct 2025 //
INDPHARMAPOST
Amgen Makes Portfolio Play Amid Scrutiny of Obesity Prospect
10 Sep 2025 //
BIOSPACE
AMGEN, Kyowa Reveal Phase 3 Rocatinlimab Study Results
09 Sep 2025 //
PR NEWSWIRE
Amgen-Zai Stomach Cancer Asset Loses OS Benefit in Final Analysis
03 Sep 2025 //
FIERCE BIOTECH
BeOne Bags $885 M in Royalty Deal on Amgen`s Imdelltra
26 Aug 2025 //
FIERCE PHARMA
Amgen Expands Repatha® Use for High Cardiovascular Risk in Adults
25 Aug 2025 //
PR NEWSWIRE
Kissei Pays Viridian $70M to Compete with Amgen in Japan
30 Jul 2025 //
FIERCE BIOTECH
Lawsuit Points to Alleged Misconduct at Amgen-Bought Biotech
25 Jul 2025 //
FIERCE PHARMA
Amgen, Zai Say Stomach Cancer Candidate Hits Phase 3 Mark
01 Jul 2025 //
BIOSPACE
Amgen`s Phase 2 obesity study of monthly Maritide results at ADA
23 Jun 2025 //
PR NEWSWIRE
Amgen to Present Maritide Data at ADA 85th Scientific Sessions
18 Jun 2025 //
PR NEWSWIRE
Amgen Drug Cuts Small Cell Lung Cancer Death risk by 40%
03 Jun 2025 //
FIERCE PHARMA
Amgen owes Regeneron $407M after defeat in PCSK9 antitrust suit
17 May 2025 //
FIERCE PHARMA
Amgen`s Tepezza Granted Marketing Authorisation in UK
07 May 2025 //
BUSINESSWIRE
FDA lifts hold on Amgen`s phase 1 obesity study
03 May 2025 //
FIERCE BIOTECH
Sandoz sues Amgen over patient access to etanercept biosimilar
14 Apr 2025 //
GLOBENEWSWIRE
Imdelltra Shows Better Survival in Small Cell Lung Cancer
11 Apr 2025 //
PR NEWSWIRE
Amgen, Kyowa Kirin Report Ph3 Rocatinlimab Data In Atopic Dermatitis
08 Mar 2025 //
PR NEWSWIRE
Amgen’s late-stage obesity trials expected to read out in ‘27
08 Mar 2025 //
FIERCE BIOTECH
Tezspire Treats Chronic Sinus Symptoms With Nasal Polyps
03 Mar 2025 //
PR NEWSWIRE
Amgen’s early-stage obesity asset put on clinical hold by FDA
05 Feb 2025 //
FIERCE BIOTECH
EU Approves Blincyto® In CD19+ B-Cell ALL Consolidation Phase
29 Jan 2025 //
PR NEWSWIRE
Amgen fends off Celltrion`s proposed Prolia biosim until June
29 Jan 2025 //
FIERCE PHARMA
FDA Approves Lumakras & Vectibix Combo For G12C Colorectal Cancer
17 Jan 2025 //
PR NEWSWIRE
FDA approves Amgen`s colorectal cancer therapy
17 Jan 2025 //
REUTERS
Sling`s oral Tepezza rival hits goal in thyroid eye disease
14 Jan 2025 //
FIERCE BIOTECH
Amgen’s IMDYLLTRA Gets UK Approval For Extensive-Stage Lung Cancer
06 Jan 2025 //
BUSINESSWIRE
BeiGene inks $150M deal to follow cancer trail blazed by Amgen
14 Dec 2024 //
FIERCE BIOTECH
Amgen invests $1B in North Carolina manufacturing expansion
09 Dec 2024 //
BIOSPACE
Blincyto Improves Survival In Pediatric B-ALL With Chemotherapy
07 Dec 2024 //
PR NEWSWIRE
Amgen, AZ`s Tezspire excels in phase 3 rhinosinusitis trial
09 Nov 2024 //
FIERCE PHARMA
Amgen gears up to launch Eylea biosim as Regeneron plots appeal
23 Oct 2024 //
FIERCE PHARMA
AMGEN Presents Phase 3 Data For UPLIZNA® In Generalized Myasthenia
15 Oct 2024 //
PR NEWSWIRE
Amgen scores late trial success for eczema and MG treatments
25 Sep 2024 //
STATNEWS
Regeneron loses bid to block Amgen`s Eylea biosim, sinking shares
24 Sep 2024 //
FIERCE PHARMA
Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
23 Sep 2024 //
REUTERS
Amgen Shares New Imdelltra Data In Small Cell Lung Cancer At WCLC 2024
09 Sep 2024 //
PR NEWSWIRE
